Supply of nintedanib and dalbavancin for Hospital Universitario de Fuenlabrada
Open · 10 days left Spain · Medicines
| Buyer | Hospital Universitario de Fuenlabrada, Servicio Madrileno de Salud (Comunidad de Madrid) |
|---|---|
| Reference | PA SUM 26-013 |
| Published | 20 October 2026 |
| Closing date | 10 November 2026, 14:00 Madrid time (CET, UTC+1) |
| Products | Nintedanib and dalbavancin for the hospital pharmacy. Tender budget EUR 81,509 excl. VAT, estimated value EUR 179,319.80. |
| Notes | Electronic submission through the Comunidad de Madrid contracting portal. Status "En plazo" (open) when checked. Published 20 Oct 2026. CPV 33690000. |
PharmaTradz is not the buyer. Read the full tender documents and any addenda on the buyer's site before bidding; they always prevail over this summary.
Typical documents for a medicines tender
- Registration in the buyer's country, or the alternative the tender accepts (for example WHO prequalification)
- GMP certificate for the manufacturing site and a certificate of pharmaceutical product (CoPP)
- Certificates of analysis, samples, stability data and labelling in the required language
- Bid security, authorisation letters and price schedules in the buyer's format
Need a supplier for this tender?
Tell us the lots, strengths and quantities. We match registered, GMP-certified manufacturers and can help with tender documents.
Request supplier quotesNew tenders in Spain
We email you when new tenders for this country are listed. Confirm first; unsubscribe any time.
Other open tenders
- Framework agreement for subcutaneous omalizumab for Hospital Clinico San Carlos, Madrid (Spain, 16 Nov)
- Framework agreement for oral anticancer medicines for Hospital Clinico San Carlos, Madrid (Spain, 27 Nov)
- Supply of linezolid 600 mg injection (Hong Kong SAR, China, 2 Nov)
- Supply of medicines for opportunistic infections (Government of Kenya) (Kenya, 3 Nov)
- Nationwide supply and distribution of adalimumab (Argentina, 3 Nov)
- Supply of ropeginterferon alfa-2b prefilled pens (Brunei, 3 Nov)
